Rationalizing the chemical space of protein-protein interaction inhibitors

Drug Discovery Today

Volumn 15, Issue 5-6, 2010, Pages 220-229

  Sperandio, Olivier ^a,b   Reynès, Christelle H ^b   Camproux, Anne Claude ^b   Villoutreix, Bruno O ^a,b  

^a CDithem Platform/IGM   (France)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; 4 [4 [2 (4 CHLOROPHENYL) 5,5 DIMETHYL 1 CYCLOHEXEN 1 YLMETHYL] 1 PIPERAZINYL] N [4 [3 MORPHOLINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 (TRIFLUOROMETHYLSULFONYL)BENZENESULFONYL]BENZAMIDE; BCL2 RELATED PROTEIN A1; BENZODIAZEPINEDIONE; BH3 PROTEIN; EPHRIN A4; G PROTEIN COUPLED RECEPTOR; METHIONINE; NERVE GROWTH FACTOR; NUTLIN 3; PHENYLALANINE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN BAK; PROTEIN BCL XL; PROTEIN BID; PROTEIN INHIBITOR; PROTEIN MDM2; PROTEIN P53; PROTEIN P75; PROTEINASE INHIBITOR; SP 4206; TRYPTOPHAN; TYROSINE; UNCLASSIFIED DRUG;

BIOINFORMATICS; CLINICAL TRIAL; DECISION TREE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG SCREENING; DRUG STRUCTURE; HUMAN; MACHINE LEARNING; PROTEIN PROTEIN INTERACTION; REVIEW;

ANIMALS; HUMANS; PHARMACEUTICAL PREPARATIONS; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN INTERACTION MAPPING;

EID: 77649233664     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2009.11.007     Document Type: Review

References (40)

1. Stumpf M.P., et al. Estimating the size of the human interactome. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 6959-6964
2. Berg T. Small-molecule inhibitors of protein-protein interactions. Curr. Opin. Drug Discov. Dev. 11 (2008) 666-674
3. Fry D.C. Drug-like inhibitors of protein-protein interactions: a structural examination of effective protein mimicry. Curr. Protein Pept. Sci. 9 (2008) 240-247
4. Villoutreix B.O., et al. In silico-in vitro screening of protein-protein interactions: towards the next generation of therapeutics. Curr. Pharm. Biotechnol. 9 (2008) 103-122
5. Wells J.A., and McClendon C.L. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 450 (2007) 1001-1009
6. Whitty A., and Kumaravel G. Between a rock and a hard place?. Nat. Chem. Biol. 2 (2006) 112-118
7. Fuller J.C., et al. Predicting druggable binding sites at the protein-protein interface. Drug Discov. Today 14 (2009) 155-161
8. Arkin M.R., and Whitty A. The road less traveled: modulating signal transduction enzymes by inhibiting their protein-protein interactions. Curr. Opin. Chem. Biol. 13 (2009) 284-290
9. Shoichet B.K. Virtual screening of chemical libraries. Nature 432 (2004) 862-865
10. Chene P. Drugs targeting protein-protein interactions. ChemMedChem 1 (2006) 400-411
11. Eyrisch S., and Helms V. Transient pockets on protein surfaces involved in protein-protein interaction. J. Med. Chem. 50 (2007) 3457-3464
12. Arkin M. Protein-protein interactions and cancer: small molecules going in for the kill. Curr. Opin. Chem. Biol. 9 (2005) 317-324
13. Clackson T., and Wells J.A. A hot spot of binding energy in a hormone-receptor interface. Science 267 (1995) 383-386
14. Lo Conte L., et al. The atomic structure of protein-protein recognition sites. J. Mol. Biol. 285 (1999) 2177-2198
15. Ma B., and Nussinov R. Trp/Met/Phe hot spots in protein-protein interactions: potential targets in drug design. Curr. Top. Med. Chem. 7 (2007) 999-1005
16. Reichmann D., et al. The molecular architecture of protein-protein binding sites. Curr. Opin. Struct. Biol. 17 (2007) 67-76
17. Arkin M.R., and Wells J.A. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat. Rev. Drug Discov. 3 (2004) 301-317
18. Park C.M., et al. Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins. J. Med. Chem. 51 (2008) 6902-6915
19. Cole C., and Warwicker J. Side-chain conformational entropy at protein-protein interfaces. Protein Sci. 11 (2002) 2860-2870
20. Clark D.E. What has virtual screening ever done for drug discovery?. Expert Opin. Drug Discov. 3 (2008) 841-851
21. Davies J.W., et al. Streamlining lead discovery by aligning in silico and high-throughput screening. Curr. Opin. Chem. Biol. 10 (2006) 343-351
22. Keskin O., et al. Characterization and prediction of protein interfaces to infer protein-protein interaction networks. Curr. Pharm. Biotechnol. 9 (2008) 67-76
23. Kitchen D.B., et al. Docking and scoring in virtual screening for drug discovery: methods and applications. Nat. Rev. Drug Discov. 3 (2004) 935-949
24. Rochet J.C. Novel therapeutic strategies for the treatment of protein-misfolding diseases. Expert Rev. Mol. Med. 9 (2007) 1-34
25. Stockwell B.R. Exploring biology with small organic molecules. Nature 432 (2004) 846-854
26. Thanos C.D., et al. Hot-spot mimicry of a cytokine receptor by a small molecule. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 15422-15427
27. Domling A. Small molecular weight protein-protein interaction antagonists: an insurmountable challenge?. Curr. Opin. Chem. Biol. 12 (2008) 281-291
28. Orry A.J., et al. Structure-based development of target-specific compound libraries. Drug Discov. Today 11 (2006) 261-266
29. Keskin O., et al. Principles of protein-protein interactions: what are the preferred ways for proteins to interact?. Chem. Rev. 108 (2008) 1225-1244
30. Pagliaro L., et al. Emerging classes of protein-protein interaction inhibitors and new tools for their development. Curr. Opin. Chem. Biol. 8 (2004) 442-449
31. Yin H., and Hamilton A.D. Strategies for targeting protein-protein interactions with synthetic agents. Angew. Chem. Int. Ed. Engl. 44 (2005) 4130-4163
32. Fry D.C. Protein-protein interactions as targets for small molecule drug discovery. Biopolymers 84 (2006) 535-552
33. Neugebauer A., et al. Prediction of protein-protein interaction inhibitors by chemoinformatics and machine learning methods. J. Med. Chem. 50 (2007) 4665-4668
34. Randic M. Molecular profiles novel geometry-dependent molecular descriptors. New J. Chem. 19 (1995) 781-791
35. Randic M. Molecular shape profiles. J. Chem. Inf. Comput. Sci. 35 (1995) 373-382
36. Kingsford C., and Salzberg S.L. What are decision trees?. Nat. Biotechnol. 26 (2008) 1011-1013
37. Gonzalez M.P., et al. In silico studies using radial distribution function approach for predicting affinity of 1 alpha,25-dihydroxyvitamin D(3) analogues for vitamin D receptor. Steroids 71 (2006) 510-527
38. Fernandez M. Quantitative structure-activity relationship to predict differential inhibition of aldose reductase by flavonoid compounds. Bioorg. Med. Chem. 13 (2005) 3269-3277
39. Hemmer M. Prediction of three-dimensional molecular structures using information from infrared spectra. Anal. Chim. Acta 420 (2000) 145-154
40. Hemmer M. Deriving the 3D structure of organic molecules from their infrared spectra. Vib. Spectrosc. 19 (1999) 151-164